Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Brivaracetam in Epilepsy
NCT00175916Phase 3Completed
- Sponsor
- UCB
- Start
- Sep 2005
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in epilepsy and Unverricht-Lundborg disease (ULD), sponsored by UCB. Primary endpoints: Percentage of Participants With at Least One Treatment-emergent Adverse Event up to 162 months, Percentage of Participants Who Withdrew Due to an Adverse Event up to 162 months and 1 more. Started Sep 2005; status: completed.
02
Drugs
brivaracetam
03
Conditions
epilepsyUnverricht-Lundborg disease (ULD)
Beyond the preview
Go deeper on NCT00175916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00175916.